A Neutral Viewpoint Of Staurosporine

Evaluable IVUS data were available at baseline and 12 months from 189 patients, with similar characteristics in the everolimus and MMF cohorts (Table S1). The mean increase in average MIT from baseline to month 12 was smaller with everolimus 1.5 mg versus MMF (0.03 �� 0.05 mm vs. 0.07 �� 0.11 mm, p http://www.selleckchem.com/products/epz-5676.html the MMF group (Table 4). The incidence of protocol-defined CAV was also lower with everolimus 1.5 mg (12.5% [11/88]) vs. MMF (26.7% [27/101], p = 0.018). Baseline eGFR was similar between groups (Table 1). Mean eGFR showed a lower posttransplant peak in the everolimus 1.5 mg arm than the MMF group, then stabilized from month 4 onwards (Figure 4). From month 12 to month 24, eGFR remained stable in both groups: mean (SD) change was �C0.67 (15.6) mL/min/1.73 m2 for everolimus 1.5 mg, and 1.6 (16.8) mL/min/1.73 m2 for MMF (Figure 4). Mean (SD) values for eGFR were 59.4 (22.8) mL/min/1.73 m2 in the everolimus 1.5 mg arm and 64.7 (28.1) mL/min/1.73 m2 with MMF at month 12 (p = 0.009), and 59.5 (22.4) mL/min/1.73 m2 and 64.5 (23.8) mL/min/1.73 m2 at month 24 (p = 0.020). At month 12 posttransplant, the main safety objective of NI of renal function for everolimus 1.5 mg versus MMF was not met since the lower limit of the CI was lower than the NI margin of �C10 mL/min/1.73 m2 (difference in mean eGFR �C5.55 mL/min/1.73 http://www.selleckchem.com/products/ly2109761.html m2, 97.5% CI [�C10.9, �C0.2]). At month 24, the difference in mean eGFR was �C6.5 mL/min/1.73 m2, 97.5% CI �C11.9, �C1.0 mL/min/1.73 m2. Everolimus 1.5 mg was associated with a mean (SD) decrease in eGFR from baseline to month 12 of �C9.2 (38.2) versus �C4.1 (31.1) mL/min/1.73 m2 with MMF (p = 0.223). The mean (SD) decrease in eGFR from month 1 to month 12, however, was significantly less with everolimus 1.5 mg versus MMF (�C8.6 [24.6] vs. �C14.6 [30.0] mL/min/1.73 m2, p = 0.009), suggesting that the loss in renal function in the everolimus group occurred mainly during the first postoperative month when cyclosporine exposure was the same http://www.selleck.cn/products/Staurosporine.html in both treatment arms. Post hoc, eGFR was analyzed for 53 centers, which achieved target cyclosporine exposure levels (10 centers were excluded that did not achieve the separation in cyclosporine exposure between everolimus and MMF groups). In this analysis, the mean (SD) eGFR decrease from baseline to month 12 was comparable (everolimus 1.5 mg [n = 229] �C6.65 (40.6) mL/min/1.73 m2 vs.